Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 4/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | PPARG | P37231 | 2/20 | 0.61 |
| ▸ | FABP2 | P12104 | 1/20 | 0.61 |
| ▸ | PPARD | Q03181 | 1/20 | 0.61 |
| ▸ | NAAA | Q02083 | 2/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | MLYCD | O95822 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 3/20 | 0.57 |
| ▸ | RAB9A | P51151 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.54 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.54 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.54 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.54 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.54 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24119885 | 0.84 | MLYCD (0.68) | ALDH1A1SMN1; SMN2NAAAL3MBTL1MLYCD | |
| SCHEMBL9760648 | 0.83 | MGLL (0.63) | — | |
| SCHEMBL16743458 | 0.82 | EPHX1 (0.63) | PPARAALDH1A1PPARGPPARDKMT2A | |
| SCHEMBL11754794 | 0.82 | NPC1 (0.69) | PPARAALDH1A1SMN1; SMN2PPARGFABP2 | |
| SCHEMBL9265536 | 0.81 | L3MBTL1 (0.86) | ALDH1A1SMN1; SMN2NAAAL3MBTL1MLYCD | |
| SCHEMBL6535660 | 0.81 | L3MBTL1 (0.86) | ALDH1A1SMN1; SMN2NAAAL3MBTL1MLYCD | |
| SCHEMBL9504178 | 0.81 | L3MBTL1 (0.86) | ALDH1A1SMN1; SMN2NAAAL3MBTL1MLYCD | |
| SCHEMBL845966 | 0.81 | L3MBTL1 (0.86) | ALDH1A1SMN1; SMN2NAAAL3MBTL1MLYCD | |
| SCHEMBL30527282 | 0.81 | L3MBTL1 (0.86) | ALDH1A1SMN1; SMN2NAAAL3MBTL1MLYCD | |
| SCHEMBL10481026 | 0.81 | L3MBTL1 (0.86) | ALDH1A1SMN1; SMN2NAAAL3MBTL1MLYCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070212302-A1 | Preparation and Use of a Stable Formulation of Allosteric Effector Compounds | ALLOS THERAPEUTICS, INC. (US) | 2007-09-13 | — | — | US | disclosed |
| EP-1496863-A4 | PREPARATION AND USE OF A STABLE FORMULATION OF ALLOSTERIC EFFECTOR COMPOUNDS | ALLOS THERAPEUTICS INC (US) | 2006-10-04 | — | — | EP | disclosed |
| US-7097825-B2 | Methods and reagents to acquire MRI signals and images | ALLOS THERAPEUTICS, INC. (US) | 2006-08-29 | — | — | US | disclosed |
| EP-1381311-A4 | METHODS AND REAGENTS TO ACQUIRE MRI SIGNALS AND IMAGES | ALLOS THERAPEUTICS INC (US) | 2005-04-27 | — | — | EP | disclosed |
| EP-1496863-A2 | PREPARATION AND USE OF A STABLE FORMULATION OF ALLOSTERIC EFFECTOR COMPOUNDS | Allos Therapeutics, Inc. (US) | 2005-01-19 | — | — | EP | disclosed |
| EP-1381311-A2 | METHODS AND REAGENTS TO ACQUIRE MRI SIGNALS AND IMAGES | Allos Therapeutics, Inc. (US) | 2004-01-21 | — | — | EP | disclosed |
| US-20030232887-A1 | Preparation and use of a stable formulation of allosteric effector compounds | ALLOS THERAPEUTICS, INC. | 2003-12-18 | — | — | US | disclosed |
| WO-2003086324-A2 | PREPARATION AND USE OF A STABLE FORMULATION OF ALLOSTERIC EFFECTOR COMPOUNDS | ALLOS THERAPEUTICS, INC. (US) | 2003-10-23 | — | — | WO | disclosed |
| US-20030017612-A1 | Methods and reagents to acquire MRI signals and images | ALLOS THERAPEUTICS, INC. | 2003-01-23 | — | — | US | disclosed |
| WO-2002068930-A2 | METHODS AND REAGENTS TO ACQUIRE MRI SIGNALS AND IMAGES | ALLOS THERAPEUTICS, INC. (US) | 2002-09-06 | — | — | WO | disclosed |
| US-5927283-A | TREATING DISEASES INVOLVING OXYGEN DEFICIENCY, IN WOUND HEALING, AND IN RESTORING OXYGEN AFFINITY OF STORED BLOOD. | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1999-07-27 | — | — | US | disclosed |
| US-5872282-A | MAINTAIN OXYGEN AFFINITY IN BLOOD WHEN STORED | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1999-02-16 | — | — | US | disclosed |
| US-5731454-A | Allosteric modifiers of hemoglobin useful for decreasing oxygen affinity and preserving oxygen carrying capability of stored blood | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1998-03-24 | — | — | US | disclosed |
| US-5705521-A | Use of allosteric hemoglobin modifiers in combination with radiation therapy to treat carcinogenic tumors | THE CENTER FOR INNOVATIVE TECHNOLOGY (US) | 1998-01-06 | — | — | US | disclosed |
| US-5677330-A | THERAPY HYPOXIA, HYPOTHERMIA, ISCHEMIC, WOUNDS, ULCERS, TISSUE TRANSPLANTS, SESPIS | THE CENTER FOR INNOVATIVE TECHNOLOGY (US) | 1997-10-14 | — | — | US | disclosed |
| WO-1997034594-A2 | USE OF ALLOSTERIC HAEMOGLOBIN MODIFIER FOR TREATING SOLID TUMORS AND INHIBITING TUMOR METASTASES | DANA-FARBER CANCER INSTITUTE (US) | 1997-09-25 | — | — | WO | disclosed |
| US-5591892-A | CARBOXYALKOXYPHENYL SUBSTITUTED INDANES | CENTER FOR INNOVATIVE TECHNOLOGY (US) | 1997-01-07 | — | — | US | disclosed |
| US-5432191-A | Ring-substituted phenoxymethyl /or substituted methyl/ carboxylates | THE CENTER FOR INNOVATIVE TECHNOLOGY (US) | 1995-07-11 | — | — | US | disclosed |
| US-5250701-A | 2-(Phthalomidomethylphenoxyalkanoic acid or ester; wound healing agents; antiischemic agents; blood storage; antidepressants; Alzheimer's disease; schizophrenia | CENTER FOR INNOVATIVE TECHNOLOGY (US) | 1993-10-05 | — | — | US | disclosed |
| US-5122539-A | Allosteric hemoglobin modifiers useful for decreasing oxygen affinity and preserving oxygen carrying capability of stored blood | CENTER FOR INNOVATIVE TECHNOLOGY (US) | 1992-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030017612-A1 | Methods and reagents to acquire MRI signals and images | TBXA2R, BID, RXFP2 | PPARA 1735/4885ALDH1A1 4399/4885SMN1; SMN2 2227/4885 |
| US-20070212302-A1 | Preparation and Use of a Stable Formulation of Allosteric Effector Compounds | PRKAA2, PDE7A, CHRM3 | PPARA 128/4885ALDH1A1 3307/4885SMN1; SMN2 718/4885 |
| US-20030232887-A1 | Preparation and use of a stable formulation of allosteric effector compounds | PRKAA2, PDE7A, CHRM5 | PPARA 172/4885ALDH1A1 3620/4885SMN1; SMN2 579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.